Advertisement
U.S. markets open in 1 hour 25 minutes
  • S&P Futures

    5,305.75
    -2.50 (-0.05%)
     
  • Dow Futures

    40,144.00
    0.00 (0.00%)
     
  • Nasdaq Futures

    18,491.00
    -12.75 (-0.07%)
     
  • Russell 2000 Futures

    2,141.60
    +3.20 (+0.15%)
     
  • Crude Oil

    82.42
    +1.07 (+1.32%)
     
  • Gold

    2,231.20
    +18.50 (+0.84%)
     
  • Silver

    24.68
    -0.07 (-0.29%)
     
  • EUR/USD

    1.0789
    -0.0041 (-0.38%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    13.03
    +0.25 (+1.95%)
     
  • dólar/libra

    1.2616
    -0.0022 (-0.17%)
     
  • USD/JPY

    151.3400
    +0.0940 (+0.06%)
     
  • Bitcoin USD

    70,747.01
    +444.11 (+0.63%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.37
    +20.39 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Medtronic Received CE Mark for Intellis Platform

Medtronic plc (NYSE: MDT) today announced that it received CE (Conformité Européenne) Mark for the Intellis(TM) platform for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) as an aid in the management of certain types of chronic pain.* Intellis, the world's smallest fully implantable SCS neurostimulator, simplifies and improves the patient experience with improved battery performance that can power the EvolveSM workflow,** which standardizes guidance and balances high-dose (HD) and low-dose (LD) SCS therapy settings. The Intellis platform is managed on the Samsung Galaxy Tab S2 tablet interface and can record and track patient activity 24/7. Intellis is now available in Europe and the United States.
One in five adults in Western Europe suffers from chronic pain, a devastating condition with a costly personal and societal impact.1 Chronic pain can negatively impact all aspects of a person's life - relationships, work productivity and activities of daily living, yet it remains under-recognized and undertreated.

See more from Benzinga

© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement